FDA Expects Greater Scientific Impact With Larger Advisory Board
This article was originally published in The Tan Sheet
Executive Summary
FDA Commissioner Andrew von Eschenbach is attempting to increase the impact of the agency's Science Board Advisory Committee by doubling the number of members and meetings
You may also be interested in...
Science Board noms
FDA requests nominations for membership on its Science Board, which advises the commissioner on technical issues, regulatory science and research agendas, according to a Sept. 5 Federal Register notice. Send nominations of individuals knowledgeable in the fields of food safety, nutrition, pharmacology, nanotechnology and other scientific disciplines to FDA at [email protected] by Oct. 6. In May, FDA Commissioner Andrew von Eschenbach said he intends to expand the board from 11 to 21 members and double its annual meetings from two to four in response to a board report pointing to the agency's deficiencies in expertise and technology (2"The Tan Sheet" June 30, 2008, p. 12)
Science Board noms
FDA requests nominations for membership on its Science Board, which advises the commissioner on technical issues, regulatory science and research agendas, according to a Sept. 5 Federal Register notice. Send nominations of individuals knowledgeable in the fields of food safety, nutrition, pharmacology, nanotechnology and other scientific disciplines to FDA at [email protected] by Oct. 6. In May, FDA Commissioner Andrew von Eschenbach said he intends to expand the board from 11 to 21 members and double its annual meetings from two to four in response to a board report pointing to the agency's deficiencies in expertise and technology (2"The Tan Sheet" June 30, 2008, p. 12)
Science Board noms
FDA requests nominations for membership on its Science Board, which advises the commissioner on technical issues, regulatory science and research agendas, according to a Sept. 5 Federal Register notice. Send nominations of individuals knowledgeable in the fields of food safety, nutrition, pharmacology, nanotechnology and other scientific disciplines to FDA at [email protected] by Oct. 6. In May, FDA Commissioner Andrew von Eschenbach said he intends to expand the board from 11 to 21 members and double its annual meetings from two to four in response to a board report pointing to the agency's deficiencies in expertise and technology (2"The Tan Sheet" June 30, 2008, p. 12)